New study The evidence supporting the potential of FAK inhibitors in treating cancers is growing, with scientists in Switzerland publishing a new preclinical study that suggests that FAK activity may be key to metastatic breast cancer cells’ ability to colonise in the brain.
In Fierce Biotech this week, journalist Helen Floersh examines the potential of FAK inhibitors in treating metastatic cancers, highlighting #Amplia’s ACCENT clinical trial in pancreatic cancer patients.
She wrote:“FAK inhibitors have shown promise in early-stage clinical trials for patients with various types of primary solid tumors, but, while seven FAK inhibitors are in phase 1 or phase 2 trials, only one of them is looking at the use of the drugs in patients with metastatic disease.”
Read the article https://lnkd.in/e85BuJWt
ATX Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)